Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> World’s Most Effective HIV Drug Rolled Out In Africa In Generic Version 29/06/2017 Fredrick Nzwili NAIROBI, Kenya - A generic version of dolutegravir (DTG), the drug of choice for the last two years for people living with HIV in high-income countries, is now available in Africa. On 28 June, the government of Kenya and drug pricing and innovation mechanism Unitaid unveiled the new first-line drug in an effort to accelerate access to better antiretroviral (ARV) drugs for her people living with HIV. It becomes the first country in Africa to introduce the generic version of drug. Continue reading -> Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Coordinated Global Solution Needed To Ensure Universal Vaccine Supply, Speakers Say 19/05/2017 Elise De Geyter Shortages of vaccines are a worldwide problem with tremendous impact on health, affecting countries of all income groups and regions, speakers said at a recent industry event. Different possible solutions for shortages of vaccines were suggested during the panel discussion. Continue reading -> G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 Monika Ermert Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 Catherine Saez Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries. Continue reading -> Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 Catherine Saez The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
World’s Most Effective HIV Drug Rolled Out In Africa In Generic Version 29/06/2017 Fredrick Nzwili NAIROBI, Kenya - A generic version of dolutegravir (DTG), the drug of choice for the last two years for people living with HIV in high-income countries, is now available in Africa. On 28 June, the government of Kenya and drug pricing and innovation mechanism Unitaid unveiled the new first-line drug in an effort to accelerate access to better antiretroviral (ARV) drugs for her people living with HIV. It becomes the first country in Africa to introduce the generic version of drug. Continue reading -> Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Coordinated Global Solution Needed To Ensure Universal Vaccine Supply, Speakers Say 19/05/2017 Elise De Geyter Shortages of vaccines are a worldwide problem with tremendous impact on health, affecting countries of all income groups and regions, speakers said at a recent industry event. Different possible solutions for shortages of vaccines were suggested during the panel discussion. Continue reading -> G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 Monika Ermert Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 Catherine Saez Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries. Continue reading -> Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 Catherine Saez The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Coordinated Global Solution Needed To Ensure Universal Vaccine Supply, Speakers Say 19/05/2017 Elise De Geyter Shortages of vaccines are a worldwide problem with tremendous impact on health, affecting countries of all income groups and regions, speakers said at a recent industry event. Different possible solutions for shortages of vaccines were suggested during the panel discussion. Continue reading -> G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 Monika Ermert Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 Catherine Saez Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries. Continue reading -> Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 Catherine Saez The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
Coordinated Global Solution Needed To Ensure Universal Vaccine Supply, Speakers Say 19/05/2017 Elise De Geyter Shortages of vaccines are a worldwide problem with tremendous impact on health, affecting countries of all income groups and regions, speakers said at a recent industry event. Different possible solutions for shortages of vaccines were suggested during the panel discussion. Continue reading -> G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 Monika Ermert Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 Catherine Saez Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries. Continue reading -> Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 Catherine Saez The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
G20 Health Ministers Receive Flurry Of Requests Ahead Of Their First-Ever Meeting 18/05/2017 Monika Ermert Civil society organisations and the Business 20 Dialogue all put their positions on the table before the opening of the first-ever meeting of G20 Health Ministers tomorrow in Berlin, Germany taking place tomorrow. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 Catherine Saez Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries. Continue reading -> Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 Catherine Saez The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 Catherine Saez Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries. Continue reading -> Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 Catherine Saez The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
New Industry Alliance Aimed At Antimicrobial Resistance 18/05/2017 Catherine Saez Pharmaceutical industry representatives today announced a new alliance to fight antimicrobial resistance. The announcement came during a meeting of the private sector of the most advanced countries. Continue reading -> Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 Catherine Saez The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
Attacks On WHO Candidate Are Defamatory, ‘Colonial’, Ambassador Says 17/05/2017 Catherine Saez The African Union delegation to the United Nations came in outspoken numbers to a press briefing today to express unshakable support for the Ethiopian candidate to be the next head of the World Health Organization, Tedros Adhanom Ghebreyesus. Continue reading -> US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
US, EU Diverge On Medical Diagnostic Patents 10/05/2017 Kim Treanor A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics. Continue reading -> MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts
MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 Elise De Geyter The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Continue reading -> Posts navigation Older postsNewer posts